NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd
Teva said the deal was worth about $6.8 billion on an enterprise basis. The deal is worth about $6.2 billion, based on the number of Cephalon shares outstanding, according to Thomson Reuters data.
Continue Reading Below
(Reporting by Lewis Krauskopf; Editing by Lisa Von Ahn)